Loading...
XFRA
CNW
Market cap7mUSD
Sep 30, Last price  
0.25EUR
Name

CoDon AG

Chart & Performance

D1W1MN
P/E
—
P/S
0.67
EPS
—
Div Yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
7.36%
Revenues
10m
+57.28%
00119,676,11300002,693,0004,045,0004,510,0005,155,0005,622,0005,980,2195,696,0006,856,0006,233,0009,803,000
Net income
-9m
L-32.79%
00-144,391,5580000-2,381,000-2,684,000-2,493,000-2,866,000-3,650,000-7,054,253-6,271,000-12,629,000-13,869,000-9,321,000
CFO
-8m
L-15.90%
00000-2,334,065-1,564,342-2,108,000-2,974,000-3,617,000-5,878,485-8,138,000-9,529,000-9,457,000-7,953,000

Profile

co.don AG, a biopharmaceutical company, develops, produces, and markets cell-based pharmaceutical products for joint preservation and the regenerative treatment of articular cartilage defects worldwide. It offers Spherox, a three dimensional chondrocyte product that is used to treat cartilage defects in adult knee joints; and co.don chondrosphere for the treatment of cartilage defects in the hip, ankle, shoulder and elbow, and knees of younger patients. The company serves accident and orthopedic surgeons. co.don AG was founded in 1993 and is headquartered in Teltow, Germany.
URL
https://www.codon.de/
IPO date
Feb 01, 2001
Employees
Domiciled in
DE
Incorporated in
DE

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT